Alnylam Grants Calando a License to Develop and Commercialize an RNAi Therapeutic Product
Target-Specific License for RNAi Intellectual Property Granted under Alnylam's InterfeRx(TM) Program
23-Aug-2006
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.